• banner image
  • banner image

Chairman's Profile

Being different and making a difference. That sums up the vision, philosophy, conviction and driving force behind Dr. Habil F Khorakiwala who revels in venturing down the road less travelled.

He founded Wockhardt in 1967. Today, the Wockhardt Group is India’s leading research-based, global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs), and Super Speciality Hospitals.

Investor Information

Our investors, Wockhardt shareowners, are an important and valued constituent of the Wockhardt stakeholder universe.

While it is a matter of regulatory compliance, we also consider it as good governance and our duty and responsibility, to keep our investors informed and updated regularly about news, events and developments that impact our business and operations.

Investor Focus


FINANCIAL RESULTS FY23 Q3

FINANCIAL RESULTS FY23 Q2

FINANCIAL RESULTS FY23 Q1

About Us

Wockhardt is a leading, research-based, global enterprise with relevance in the fields of pharmaceuticals, biotechnology, and healthcare services.

Our multinational R&D and manufacturing facilities are spread across India, USA, UK and UAE, and our worldwide marketing presence includes over 30 countries across 6 continents. 

Our Products

Team Wockhardt

Team Wockhardt exhibits a global work culture and mindset in complete alignment with organisational goals and strives to excel, collectively as well as individually. Whole-heartedly adopting the corporate credo of Life Wins, Team Wockhardt has in place a strong leadership team with the bandwidth to ably lead the organisation into the future.

Life Wins

Global Reach

India Website India Website India Website rassia Shendra Aurangabad Shendra Aurangabad Shendra Aurangabad Shendra Aurangabad Switzerland Website London Website Ireland Website - USA East Website France Website

INVESTOR FOCUS

FINANCIAL RESULTS
FY23 Q4

FINANCIAL RESULTS
FY23 Q3

FINANCIAL RESULTS
FY23 Q2

WOCKHARDT’S Q4 FY23 3 FOLD JUMP IN EBITDA OVER Q4 FY22

WOCKHARDT’S Q3 FY23 EBITDA GROWTH @37% OVER Q2 FY23

WOCKHARDT’S Q2 FY23 TOPLINE GROWTH @14% AND EBITDA GROWTH @369% OVER PREVIOUS QUARTER

Beyond Pharmaceuticals

6 new drugs under development, accorded QIDP status by US FDA and in Phase III clinical stage, are being developed as novel antibiotics and are expected to significantly aid global efforts against Antimicrobial Resistance (AMR).

A chain of super-speciality hospitals offering world-class tertiary and quaternary healthcare services, Wockhardt Hospitals has built a reputation for quality, professionalism and positive outcomes.

Wockhardt Foundation implements several social initiatives to improve the quality of life of the underprivileged sections of society and manages to make a difference to over four million lives every year.
Wockhardt Global School, Aurangabad, is a not-for-profit initiative dedicated to developing a student community of lifelong learners that imbibes skills, knowledge and values required for global citizenship.

A chain of super-speciality hospitals offering world-class tertiary and quaternary healthcare services, Wockhardt Hospitals has built a reputation for quality, professionalism and positive outcomes.

Wockhardt Foundation implements several social initiatives to improve the quality of life of the underprivileged sections of society and manages to make a difference to over four million lives every year.
Wockhardt Global School, Aurangabad, is a not-for-profit initiative dedicated to developing a student community of lifelong learners that imbibes skills, knowledge and values required for global citizenship.